TREATMENT OF PAGET'S DISEASE WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)
- 1 April 1979
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 313 (8120) , 799-803
- https://doi.org/10.1016/s0140-6736(79)91318-7
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Treatment of Paget's disease with combined calcitonin and diphosphonate (EHDP)Metabolic Bone Disease and Related Research, 1978
- Sodium Etidronate in the Treatment of Paget's Disease of BoneAnnals of Internal Medicine, 1977
- Diphosphonate Therapy of Paget's Disease of BoneJournal of Clinical Endocrinology & Metabolism, 1977
- Etidronate disodium in postmenopausal osteoporosisClinical Pharmacology & Therapeutics, 1976
- Ethane-1-hydroxy-1, 1-diphosphonate (EHDP) effects on growth and modeling of the rat tibiaCalcified Tissue International, 1975
- DISODIUM ETHANE-1-HYDROXY-1, 1-DIPHOSPHONATE (E.H.D.P.) IN PAGET'S DISEASEThe Lancet, 1975
- Treatment of Paget disease of bone (osteitis deformans). Results of a one-year study with sodium etidronatePublished by American Medical Association (AMA) ,1974
- Influence of Disodium Etidronate on Clinical and Laboratory Manifestations of Paget's Disease of Bone (Osteitis Deformans)New England Journal of Medicine, 1973
- Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of ratsCalcified Tissue International, 1973
- Skeletal Renewal and Metabolic Bone DiseaseNew England Journal of Medicine, 1969